Alternatives

Life Sciences

Our Life Sciences team’s domain expertise, deep network, and advisory capabilities position us to identify the next generation of leading therapeutics, tools, and diagnostics companies.
At a Glance
$650
MillionAssets Under Management
25
YearsAverage Experience of Investment Committee
6
Investment Themes

Source: Goldman Sachs Asset Management. As December 31, 2023

What Makes Us Different

Sourcing

We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives.

Capital Formation

We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.

Value Creation

We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, execute, and achieve strong exits.

Select Investments
All6
Immunology
Biotechnology company focused on discovering and developing medicines targeting a class of cell signaling receptors known to play important roles in various diseases.
Precision Medicine
Biotechnology company focused on discovering and developing small molecule precision medicines by targeting cancer-associated mutations that have historically been challenging to drug.
Immunology
Clinical-stage biotechnology company focused on developing novel biologics-based treatments for cancers.
Precision Medicine
Biopharmaceutical company focused on discovering the next generation of precision medicines by targeting molecular machines that underlie human disease.
Precision Medicine
Precision neuroscience biotechnology company developing small molecule therapeutics to address significant unmet needs in neurological disorders.
Precision Medicine
Biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer.

Source: Goldman Sachs Asset Management as of December 31, 2023.Investments were selected to highlight the largest investment made as of December 31, 2023. We believe these selected case studies should be considered as a reflection of our investment process, and references to these particular assets/portfolio companies should not be considered a recommendation of any particular security, investment, or portfolio company.  Any mention of an investment decision is intended only to illustrate our investment strategy and is not indicative of the performance of our strategy as a whole. It should not be assumed that any investment decisions shown will prove to be profitable or any future investment decisions will be profitable or equal the performance of the investments discussed herein. The holdings and/or allocations shown may not represent all of the strategy’s investments. Please contact your Goldman Sachs Asset Management representative to obtain the holdings presented above as well as each holding’s contribution to performance and a complete list of past recommendations. Please see additional disclosures in the appendix.

Our Leadership Team
Our team comprises experienced life sciences investors with deep domain expertise across disciplines.
Avatar
Amit Sinha
Head of Life Science Investing
Avatar
Colin Walsh
Managing Director
Avatar
Josh Richardson
Managing Director
Avatar
Kevin Xu
Managing Director
Advisory Board
Our investment team is complemented by an industry leading Advisory Board comprised of academics, clinicians, scientific experts, and entrepreneurs.
Avatar
Lloyd Minor
Dean, Stanford University School of Medicine
Avatar
Diane Mathis
Morton Grove-Rasmussen Chair of Immunohematology, Harvard Medical School
Avatar
David Chang
CEO, Allogene
Avatar
Ross Levine
Deputy Physician-in-Chief and Translational Research, Memorial Sloan Kettering
Avatar
Anima Anandkumar
Bren Professor of Computing and Mathematical Sciences of the California Institute of Technology and Senior Director of AI Research at NVIDIA
Avatar
Sean Nolan
Biotech Executive